Target Name: FTH1
NCBI ID: G2495
Review Report on FTH1 Target / Biomarker Content of Review Report on FTH1 Target / Biomarker
FTH1
Other Name(s): ferritin heavy chain 1 | Ferritin heavy chain, N-terminally processed | FRIH_HUMAN | apoferritin | ferritin, heavy polypeptide 1 | ferritin H subunit | Ferritin heavy chain | Ferritin H subunit | placenta immunoregulatory factor | PIG15 | Ferritin heavy polypeptide 1 | HFE5 | proliferation-inducing protein 15 | FTH | cell proliferation-inducing gene 15 protein | FTHL6 | Cell proliferation-inducing gene 15 protein | Ferritin heavy chain 1 | PLIF | FHC

Unlocking the Potential of FTH1: A Promising Drug Target and Biomarker

Introduction

Ferritin heavy chain 1 (FFH1) is a protein that plays a critical role in the regulation of hematopoietic stem cells (HSCs) proliferation, maturation, and survival. High levels of FTH1 have been associated with various diseases, including anemia, thrombosis, and cancer . Therefore, the discovery and development of potential drug targets and biomarkers for FTH1 have significant implications for the prevention and treatment of these diseases.

Drug Targets

FFH1 has been identified as a potential drug target due to its unique structure and bioavailability. FTH1 is a transmembrane protein that consists of four transmembrane domains and a cytoplasmic tail. It plays a vital role in the regulation of hematopoietic stem cell (HSC) proliferation and differentiation by promoting the growth, survival, and proliferation of HSCs.

FFH1 has been shown to play a critical role in the regulation of HSC life cycle, including the control of cell cycle progression, apoptosis, and stem cell self-renewal. Additionally, FTH1 has been linked to the development and maintenance of various diseases, including cancer, thrombosis, and anemia. Therefore, targeting FTH1 with drugs has the potential to treat a variety of conditions.

Biomarkers

FFH1 has also been identified as a potential biomarker for various diseases, including cancer, thrombosis, and anemia. The levels of FTH1 have been shown to be elevated in various diseases, including cancer, thrombosis, and anemia. Therefore, measuring the levels of FTH1 may be a promising biomarker for the early detection and diagnosis of these diseases.

Methods

To determine the potential drug targets and biomarkers for FTH1, researchers have used a variety of techniques, including in vitro and in vivo assays, high-throughput screening, and bioinformatics analysis. In vitro assays, such as the 3D-fluorescence assay, have been used to measure the effects of drugs on the expression and activity of FTH1. In addition, in vivo assays, such as the bone marrow assay, have been used to measure the effects of drugs on the bone marrow-derived cells and their proliferation.

Results

The results of these studies have shown that FTH1 is a critical regulator of HSCs and that it plays a vital role in the regulation of various diseases, including cancer, thrombosis, and anemia. Additionally, the levels of FTH1 have been shown to be elevated in various diseases, including cancer, thrombosis, and anemia.

Conclusion

In conclusion, FTH1 is a promising drug target and biomarker for the prevention and treatment of various diseases. The discovery and development of potential drugs and biomarkers for FTH1 have significant implications for the future of medicine and may lead to the prevention and treatment of diseases that are currently treated with limited options. Further research is needed to fully understand the role of FTH1 in the regulation of HSCs and to develop effective drugs and biomarkers for FTH1.

Protein Name: Ferritin Heavy Chain 1

Functions: Stores iron in a soluble, non-toxic, readily available form. Important for iron homeostasis. Has ferroxidase activity. Iron is taken up in the ferrous form and deposited as ferric hydroxides after oxidation. Also plays a role in delivery of iron to cells. Mediates iron uptake in capsule cells of the developing kidney (By similarity)

The "FTH1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FTH1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

FTH1P1 | FTH1P10 | FTH1P11 | FTH1P12 | FTH1P2 | FTH1P20 | FTH1P22 | FTH1P24 | FTH1P3 | FTH1P4 | FTH1P5 | FTH1P7 | FTH1P8 | FTHL17 | FTL | FTLP16 | FTLP2 | FTLP3 | FTLP7 | FTMT | FTO | FTO-IT1 | FTOP1 | FTSJ1 | FTSJ3 | FTX | FUBP1 | FUBP3 | FUCA1 | FUCA2 | Fucosyl GM1 | Fucosyltransferase | FUNDC1 | FUNDC2 | FUNDC2P2 | FUNDC2P3 | FUOM | FURIN | FUS | FUT1 | FUT10 | FUT11 | FUT2 | FUT3 | FUT4 | FUT5 | FUT6 | FUT7 | FUT8 | FUT8-AS1 | FUT9 | FUZ | FXN | FXR1 | FXR2 | FXYD1 | FXYD2 | FXYD3 | FXYD4 | FXYD5 | FXYD6 | FXYD6-FXYD2 | FXYD7 | FYB1 | FYB2 | FYCO1 | FYN | FYTTD1 | FZD1 | FZD10 | FZD10-AS1 | FZD2 | FZD3 | FZD4 | FZD4-DT | FZD5 | FZD6 | FZD7 | FZD8 | FZD9 | FZR1 | G protein-Coupled Inwardly-Rectifying Potassium Channel (GIRK) | G Protein-Coupled Receptor Kinases (GRKs) | G0S2 | G2E3 | G2E3-AS1 | G3BP1 | G3BP2 | G6PC1 | G6PC2 | G6PC3 | G6PD | GA-binding protein | GAA | GAB1 | GAB2 | GAB3 | GAB4 | GABA(A) receptor | GABARAP